If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Update on AGM Procedure

8 Apr 2020 07:00



Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides an update on its upcoming Annual General Meeting (“AGM”), scheduled to be held at the offices of Shakespeare Martineau at 60 Gracechurch Street, London EC3V 0HR, United Kingdom at 10.30 a.m. on April 16, 2020.

The Company currently plans to hold its AGM as scheduled, however given the UK Government’s present restrictions on public gatherings of more than two people, the Board requests shareholders to vote by proxy rather than attend the AGM in person. Any shareholders seeking to attend the AGM in person will be refused entry.

By way of reminder, the deadline for delivery of completed proxy forms by holders of the Company’s ordinary shares is 10.30 a.m. on April 14, 2020. The equivalent deadline for proxy voting by holders of the Company’s American Depository Shares is 10 a.m. on April 9, 2020.

Verona Pharma continues to review the UK Government’s restrictions and recommends that shareholders monitor the Company's website and announcements for any updates in relation to the AGM. In the event that its AGM arrangements have to change, the Company will issue a further communication via a regulatory information service.

A copy of our AGM Notice and Annual Report are available on the Company’s website within the Investors section, www.veronapharma.com.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Victoria Stewart, Director of Communicationsinfo@veronapharma.com
  
N+1 SingerTel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)Tom Salvesen (Corporate Broking) 


Date   Source Headline
13th Sep 20167:00 amPRNHalf-year Report
12th Sep 20167:00 amPRNAppointment of Vikas Sinha as Non-Executive Director
30th Aug 20167:00 amPRNData on RPL554 to be presented at ERS Congress
10th Aug 20169:59 amPRNNotice of Results
9th Aug 20162:16 pmRNSDirector Dealing
5th Aug 20169:27 amRNSHolding(s) in Company
4th Aug 20163:26 pmPRNGrant of Share Options
4th Aug 20168:45 amRNSHolding(s) in Company
3rd Aug 20169:03 amRNSHolding(s) in Company
3rd Aug 20168:43 amRNSHolding(s) in Company
3rd Aug 20168:37 amRNSHolding(s) in Company
2nd Aug 20164:26 pmRNSHolding(s) in Company - Replacement
2nd Aug 201611:26 amRNSHolding(s) in Company
1st Aug 20163:57 pmRNSHolding(s) in Company
1st Aug 201611:40 amRNSHolding(s) in Company
1st Aug 201611:20 amRNSHolding(s) in Company
29th Jul 20168:06 amPRNAdmission of Placing Shares
22nd Jul 201611:32 amPRNResult of GM
1st Jul 20168:00 amPRNNotice of GM
27th Jun 20161:42 pmPRNResult of AGM
20th Jun 20167:00 amPRNProposed Placing and Notice of General Meeting
17th Jun 20164:54 pmPRNProposed Placing and Notice of General Meeting
3rd Jun 20165:26 pmPRN2015 Annual Report and Accounts, Notice of AGM
3rd Jun 20167:00 amPRNFinal Results
27th May 20162:48 pmPRNNotice of Results
10th May 20167:00 amPRNAdd-on Phase II RPL554 study
4th May 20167:00 amPRNVerona to present RPL554 at the ATS Conference
19th Apr 20163:16 pmPRNChange of Registered Office
15th Apr 20164:08 pmRNSHolding(s) in Company
21st Mar 20167:00 amPRNVerona Pharma: 2015 in review
15th Mar 20167:00 amPRNPositive results from RPL554 dose-finding study
10th Feb 20162:47 pmPRNGrant of Share Options
21st Jan 201612:24 pmRNSDirector Dealing
11th Jan 20167:00 amPRNDirectorate Change
3rd Dec 20154:02 pmPRNDirector Dealing
1st Dec 20155:11 pmRNSHolding(s) in Company
11th Nov 20157:00 amPRNRPL554 paper published in American Journal of Physiology
5th Nov 20157:00 amPRNPatient enrolment completed in RPL554 PhIIa studies
14th Oct 20157:00 amPRNStart of RPL554 Phase IIa combination study
8th Oct 201511:30 amPRNRPL554 data presented at North American CF Conference
29th Sep 20157:00 amPRNPositive headline data from RPL554 study
8th Sep 20157:00 amPRNBoard Changes
8th Sep 20157:00 amPRNHalf-yearly Report
27th Aug 20157:00 amPRNNotice of Results
7th Jul 20154:45 pmPRNDirector Dealing
17th Jun 20155:02 pmPRNDirector Dealings
12th Jun 20157:00 amPRNSecondary listing in Germany
11th Jun 20151:00 pmPRNResult of AGM
11th Jun 20157:00 amPRNRPL554 Phase 2a trial started
8th Jun 20157:00 amPRNRPL554 MAD study complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.